(Q50938443)

25 March 2018

title

The minimal effective exemestane dose for endocrine activity in advanced breast cancer. (English)

1 reference

25 March 2018

author

Antonia Martinetti

4

1 reference

25 March 2018

Luigi Mariani

5

1 reference

25 March 2018

author name string

E Bajetta

1

1 reference

25 March 2018

N Zilembo

2

1 reference

25 March 2018

C Noberasco

3

1 reference

25 March 2018

L Ferrari

6

1 reference

25 March 2018

R Buzzoni

7

1 reference

25 March 2018

M Greco

8

1 reference

25 March 2018

C Bartoli

9

1 reference

25 March 2018

I Spagnoli

10

1 reference

25 March 2018

G M Danesini

11

1 reference

25 March 2018

S Artale

12

1 reference

25 March 2018

J Paolini

13

1 reference

25 March 2018

publication date

1 April 1997

1 reference

25 March 2018

European Journal of Cancer

published in

1 reference

25 March 2018

volume

33

1 reference

25 March 2018

page(s)

587-591

1 reference

25 March 2018

issue

4

1 reference

25 March 2018

Source of Estrogen Production in Postmenopausal Women1

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Post-menopausal estrogen production, with special reference to patients with mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Potential clinical role of new aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Urinary 17-hydroxycorticosteroids measured by gas-liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900494-7

7 January 2021

10.1016/S0959-8049(96)00494-7

Identifiers

DOI

1 reference

25 March 2018

PubMed ID

9274439

1 reference

25 March 2018